Life Sciences 360

Medical misinformation, life sciences burnout, and AI-powered content creation collide in this episode with Dr. Ome Ogbru, founder & CEO of AINGENS and creator of MACg (Medical Affairs Content Generator). 

Learn how AI in biotech is tackling the complexities of medical affairs—from literature review and content automation to compliance and regulatory writing.

⚡️ WHAT YOU’LL LEARN:

- Why medical affairs and regulatory teams can’t rely on ChatGPT alone.

- How MACg integrates real‑time PubMed search, citation generation, and secured collaboration to streamline scientific writing 

- Why MACg users report up to 50 % faster writing and 50–70 % faster medical-legal review.

- Why AI platforms like MACg must be purpose-built for life sciences (GDPR & SOC 2 compliant).

- What is “human-in-the-loop” AI workflow—and how it balances automation and review to maintain accuracy and trust.

- Real-world use cases: scientific summaries, medical info letters and more.

🎙️ Guest: Ome Ogbru | Founder and President of AINGENS
🔗 Connect with Ome: LinkedIn

For transcripts, check out the podcast website - www.lifesciencespod.com

What happens when 3,500 staffers lose their jobs due to FDA layoffs, venture capital (VC) term sheets shrink, and AI drug-discovery startups raise $600 million rounds? 

Executive recruiter William Holodnak (ex-Fidelity, global biotech headhunter) breaks down 2025’s wild hiring market—and how founders can still build A-teams.

In this episode you’ll learn:

- Why the April-1 FDA layoffs could delay approvals—and open new career doors for ex-regulators. 

- The three traits VCs demand in first-time biotech CEOs during a funding slump. 

- How AI-driven platforms like Isomorphic Labs raised mega-rounds in a down market. 

- Immunology’s surge and why oncology startups are pivoting. 

- Board-level recruiting tactics that de-risk your Series B.

🎙️ Guest: William Holodnak | Founder and President of Occam Global
🔗 Connect with Bill: LinkedIn

📌 Chapters:
00:00 Intro
05:45 Cambridge—“the Florence of Biotech” origin story
08:20 FDA layoffs: threat or opportunity?
13:30 Biotech venture capital mood swings & funding checkpoints
18:00 What VCs really screen for in scientific founders
25:05 The “horses for courses” CEO model explained
33:00 Hot therapeutic areas: AI drug discovery, immunology, repurposing
38:30 Why boards need operators, not just investors
47:00 Career improvisation: William’s closing advice

For transcripts, check out the podcast website - www.lifesciencespod.com

Why Most Healthcare Brands Fail (And How to Fix It)

In this episode, Holley Miller, Founder and President of Grey Matter Marketing, reveals why most medtech and life sciences companies fail to connect with their audience—and how to fix that with brand clarity and strategic storytelling.

You’ll learn how marketing in regulated industries is evolving, why flashy tactics often fall flat, and how brand equity is built through consistency, credibility, and emotional connection. Holley also shares lessons from working with emerging startups and large enterprises, offering a strategy for aligning commercial goals with patient and provider trust.

🎙️ Guest: Holley Miller | Founder and President of Grey Matter Marketing
🔗 Connect with Holley: LinkedIn

📌 Chapters:
00:00 The Journey of Grey Matter: 19 Years in Life Science Marketing
02:45 Evolution of Marketing in Life Sciences
05:59 Category Design: Creating and Owning a Market
08:54 Understanding Problems: The Key to Category Creation
12:02 Building the Right Team for Success
14:57 Painkillers vs. Vitamins: Motivating Change in Healthcare
27:30 Life Sciences Market Domination Framework
34:27 The Four Pillars of Market Success
42:31 Market Domination Scorecard: Assessing Your Strategy
45:09 What Matters: The Impact of Your Work
48:39 Finding Your Superpower

Subscribe for more insights on the latest in Life Sciences!

For transcripts, check out the podcast website - www.lifesciencespod.com

Solving the “Undruggable” Disease Problem with Goldilocks Molecules

In this episode, Christian Schafmeister, Founder and President of Third Law Molecular, reveals a new class of therapeutics designed to target what most consider “undruggable” diseases—conditions like Alzheimer’s, certain cancers, and rare genetic disorders.

Christian explains the science behind spiroligomers—modular, mid-sized molecules that act like molecular LEGOs, offering the perfect balance between small molecules and biologics. Learn how his team created a library of 4.5 billion molecules and what makes these structures uniquely suited to bind difficult protein targets, including disordered proteins and intracellular surfaces.

We also talk about the Goldilocks Zone of drug design, how Third Law’s chemistry was born out of academic and defense-backed research, and why the future of drug discovery may lie in designing therapeutics that are just right.

🎙️ Guest: Christian Schafmeister | Founder and President at ThirdLaw Molecular
🔗 Connect with Christian: LinkedIn
🔗 ThirdLaw Molecular Website
🔗 Spiroligomers Presentation

📌 Chapters:
00:00 Introduction to Undruggable Diseases
01:30 Discovering Spiroligomers: A New Class of Molecules
08:04 Challenges in Targeted Drug Discovery
09:31 Building a Library of Molecules
14:47 The Birth of Third Law Molecular
17:19 The Goldilocks Molecule Concept
19:56 Applications in Cancer and Other Diseases
21:24 Collaborations with Big Pharma
23:39 Handling Clinical Trials
27:20 Future Directions and Industry Insights

Subscribe for more insights on the latest in Life Sciences!

For transcripts, check out the podcast website - www.lifesciencespod.com

Why Startups Fail (Hint: It’s Not the Innovation)

In this episode, Carlo Odicino, CEO and Founder at One TEAM Partners, shares the real reasons why most early-stage life sciences companies struggle to survive—and it has nothing to do with bad science.

Learn the hidden pitfalls of scaling too fast, confusing innovation with execution, and chasing too many priorities at once. Carlo offers practical strategies for building focus, setting boundaries, and creating a people-first culture that actually scales. You’ll also learn why execution beats experimentation when commercial success is the goal—and how to stay aligned with investors without over-promising.

This conversation is packed with actionable advice for startup leaders, biotech founders, and anyone facing the complexities of early-stage growth.

🎙️ Guest: Carlo Odicino | CEO and Founder at One TEAM Partners
🔗 Connect with Carlo: LinkedIn
🔗 One Team Partners Website

📌 Chapters:
00:00 The Innovation-Execution Tension
07:30 Managing Investor Expectations
17:48 Establishing Core Values in Organizations
24:56 Work-Life Integration vs. Balance
35:11 The Role of Human Connection in Innovation

Subscribe for more insights on the latest in Life Sciences!

For transcripts, check out the podcast website - www.lifesciencespod.com